Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia
US5508279A · kind A · utility
5Cited by
2References
8Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 7, 1994 |
| Grant date | Apr 16, 1996 |
| Priority date | — |
| Expiry date | Mar 7, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are disclosed utilizing the optically pure (+) isomer of doxazosin. This compound is a potent drug for the treatment of benign prostatic hyperplasia while avoiding the concomitant liability of hypotensive effects associated with the racemic mixture of doxazosin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.